Stephen D. Wiviott, MD, FACC is a graduate of University of Pennsylvania and Harvard Medical School (HMS, Honors). He served as a Medicine resident and Chief Medical Resident at Brigham and Women’s Hospital (BWH). Following his medical residency training, he served as a Cardiology fellow at Johns Hopkins Hospital. He is Associate Professor of Medicine at Harvard Medical School, and a Senior Investigator with the TIMI study group. He attends in the Levine Cardiovascular Intensive Care Unit and general Cardiology service at Brigham and Women's Hospital.
As an investigator, Dr. Wiviott has played important roles in the planning, implementation, leadership, and interpretation of multicenter, national, and international clinical trials in acute coronary syndromes including the TRITON-TIMI 38 trial, PRINCIPLE-TIMI 44 and of the TIMI 38 Coronary Stent Registry. He has also served in leadership of trials of secondary prevention of cardiovascular disease as global PI of DECLARE – TIMI 58, CAMELLIA – TIMI 61, and DAPA ACT HF – TIMI 68 assessing CV safety and efficacy of metabolic therapies. He is the Chairman of the TIMI Clinical Events Committee and recognized as an expert in event definitions and adjudications. Dr. Wiviott is an author of over 200 peer-reviewed publications in major medical and cardiovascular journals including 15 original articles in the New England Journal of Medicine. He was named in 2014 and 2017 by Thomson Reuters and Clarivate Analytics as one of “The World’s Most Influential Scientific Minds” and in 2016-2020 as a “Highly Cited Researcher,” recognitions inclusive of the top 1% of researchers in Clinical Medicine by citation.
Building on his trials experience, Dr. Wiviott serves as Vice President for Clinical Trials Research and Administration for Mass General Brigham and leads the Mass General Brigham Clinical Trials Office. The CTO provides contracting, budgeting, and clinical trial management services for Mass General Brigham hospital investigators and industry sponsors and is tasked with supporting and growing clinical trials research at Mass General Brigham.
